1. Scrip

PureTech Takes On Roche With Improved IPF Drug

Modified Version Of Esbriet Seems Safer

 
• By Ayisha Sharma

The firm’s lead candidate has shown strong tolerability in an early-stage trial for idiopathic pulmonary fibrosis, sparking hopes for registration-enabling studies and a streamlined development plan.      

Squiggly lines from start to finish line, a straight line from start to finish underneath. Streamlined concept.
PureTech Hopes To Piggyback Off Esbriet Data For A Smoother Filing • Source: Alamy

PureTech Health plc will start a dose-ranging study of LYT-100, a modified version of Roche Holding AG’s idiopathic pulmonary fibrosis (IPF) blockbuster Esbriet as part of its plan to advance the candidate into registrational development via a simplified US regulatory pathway.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D